Success in this area means ensuring the right therapy reaches the patient in a form that is stable, effective, and ready for ...

To close the innovation-access gap, there is a desperate need for an infrastructure rooted in trust. That means complementing ...

At BIO 2025, pharmaphorum Editor in Chief spoke with Hanadie Yousef, CEO of Juvena Therapeutics, a biotech focused on discovering and developing tissue-restorative biologics for chronic age-related ...

Don’t miss the return of the Translational Digital Pathology & AI Summit, uniting 60+ leading biopharma pioneers driving the ...

Following a pre-Congress press briefing and data presented onsite at ASCO 2025 itself, pharmaphorum spoke with Dr Victoria ...

The NNF – a philanthropic non-profit organisation that owns a controlling stake in Danish drugmaker Novo Nordisk – has been ...

The Obesity Drug Development Summit Europe is your perfect platform to be in a prime position to be at the forefront of this ...

The Synthetic Human Genome (SynHG) Project, launched on the 25th anniversary of the mapping of the human genome, is being ...

The Neuropsychiatric Drug Development Summit returns for its eighth year as the industry’s flagship forum capturing ...

The European Commission has cleared the high-strength formulation of Eylea (aflibercept) with an extended treatment interval ...

FDA Commissioner Dr Martin Makary took the stage at BIO 2025 to detail the way he and his team have been challenging “deeply held assumptions” about how the FDA ought to do its work. “We have got to ...

New research reveals some significant imbalances between healthcare professionals' (HCP) demand and industry's provision of medical information, based on content types, channels and format.